<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo





                          August 17, 2023

       Matthew Angel, Ph.D.
       Chief Executive Officer and President
       Eterna Therapeutics Inc.
       1035 Cambridge Street, Suite 18A
       Cambridge, MA 02141

                                                        Re: Eterna Therapeutics
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed August 14,
2023
                                                            File No. 333-273977

       Dear Matthew Angel:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tim
Buchmiller at (202) 551-3635 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Win Rutherfurd, Esq.
</TEXT>
</DOCUMENT>
